Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

BACKGROUND. Anlotinib is a tyrosine kinase inhibitor inhibiting angiogenesis. This multicenter, randomized phase II trial aimed to investigate the efficacy and safety of anlotinib in comparison with sunitinib as first‐line treatment for patients with metastatic renal cell carcinoma (mRCC). MATERIALS...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Zhou, Ai‐Ping, Bai, Yuxian, Song, Yan, Luo, Hong, Ren, Xiu‐Bao, Wang, Xiuwen, Shi, Benkang, Fu, Cheng, Cheng, Ying, Liu, Jiyan, Qin, Shukui, Li, Jun, Li, Hanzhong, Bai, Xianzhong, Ye, Dingwei, Wang, Jinwan, Ma, Jianhui
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2019
Soggetti:
Genitourinary Cancer
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693716/
https://ncbi.nlm.nih.gov/pubmed/30902918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0839
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi